SEC Filing Summary: Leisure Acquisition Corp. (LACQ)
Business Context and Reporting Period
This Form 8-K was filed by Leisure Acquisition Corp. (LACQ) on May 7, 2021. The filing serves as a Regulation FD disclosure regarding a press release issued by Ensysce Biosciences, Inc. ("Ensysce"). The document highlights Ensysce's upcoming participation in a conference to present data on nafamostat delivery to airways for inhibiting SARS-CoV-2. The filing also references an ongoing proposed transaction between LACQ and Ensysce, noting that relevant materials, including a Form S-4 registration statement, have been or will be filed with the SEC.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Leisure Acquisition Corp. or Ensysce Biosciences, Inc. This report focuses on regulatory disclosure and transactional updates rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary material event is the announcement of Ensysce's conference presentation regarding its therapeutic candidate and the continued progression of the merger transaction between LACQ and Ensysce.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates that Ensysce will present information on nafamostat for SARS-CoV-2 inhibition. It directs investors to the definitive proxy statement/prospectus for detailed information regarding the proposed transaction between LACQ and Ensysce.
Risks and Contingencies: The document includes a non-solicitation statement, clarifying that this communication is not an offer to sell or a solicitation of an offer to buy securities. It warns that no sale of securities will occur in jurisdictions where such an offer would be unlawful prior to registration. Investors are urged to read the Form S-4 and proxy materials for important information about the transaction.
Key Facts for Investor Verification
- Verify the details of the proposed transaction between Leisure Acquisition Corp. and Ensysce Biosciences, Inc. in the Form S-4 registration statement.
- Review the attached press release (Exhibit 99.1) for specific data regarding Ensysce's nafamostat presentation.
- Confirm the status of the proxy statement/prospectus and the date of the special meeting for stockholder voting.
- Note that this 8-K filing does not contain audited financial statements or specific financial performance metrics for the reporting period.